One of the key success factors we’ve identified in our orphan drug consulting and specialty drug consulting practices after over 50 launches and re-launches of orphan and specialty pharmaceuticals, is that the pharma client must have one overarching integrated strategy and corresponding measure of success for their pharma launch plan or re-launch. If activities across the various organizational segments (aka silos) are not highly coordinated then marketing, sales, sales incentive compensation, payer strategy, reimbursement support services and data and reporting can very often run off in significantly disparate directions, some of which can literally be pulling in opposite directions. BioSolutia calls this phenomenon “silofication”. The larger the organization, the higher the probability that silofication can occur. We have found in our orphan drug consulting and specialty drug consulting experiences, designating clear overall accountability and decision-making is one of the keys to success, as is using BCSDS – the BioSolutia Commercialization Strategy Development System.
As we described in an earlier entry, each orphan drug launch or product commercialization situation is different and requires a uniquely customized strategy. Through of over 100 years of combined experience in the orphan drug consulting and specialty pharmaceutical consulting industry, we have developed a battle-tested, trademarked process known as BCSDS – the BioSolutia Commercialization Strategy Development System. BCSDS develops a comprehensive 360 degree assessment based upon the 5 Ps (Stakeholders) and the specific product’s 15 Cs (Key Considerations). The result is one overarching integrated strategy for your orphan drug launch, expertly tailored to your unique product situation. Our track record of success in pharma consulting services has allowed us to continually refine this uniquely effective, trademarked process.
Bill creating more orphan drugs would cost taxpayers and patients – A provision allowing more medicines to receive orphan drug status will cost consumers billions of dollars, an analysis said.
Law for rare disease drugs needs revamping – A team of researchers argues that drug makers are exploiting loopholes in the Orphan Drug Act, which gives companies incentives to create medicines for rare diseases.